Clinical trial · Interventional
Iscar for Supplemental Care in Stage IV Lung Cancer
NCT00079794CI-TRIAL-00001116completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Iscar | Drug | — | UNRESOLVED |
| mistletoe | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage IV NSCLC patients who receive standard chemotherapy Exclusion criteria: * Known allergy to Viscum Album L. * Concomitant use of other mistletoe products * Concomitant use of mushroom glucan and proteoglycan extracts * Concomitant use of thymus extract products * Inability to self-report quality of life utilizing assessment tools * Ongoing steroid or ACTH therapy * Co-morbid immunocompromised state * Pregnancy * Participation in other clinical trials
References
Publications (0)
Data not yet available
No reference posted for this study.